Robin Alan L

Steger Jennifer S, Capó-Aponte José E, Papp Alexandra, Schulte Alexandra J, Grewal Eric P, Song Allisa J et al.

Microdrops via Nanodropper showed better IOP lowering, reduced bottle exhaustion, and fewer side effects than conventional drops, potentially improving glaucoma treatment adherence and control.

Puthuran George Varghese, Palmberg Paul Frederic, Talla Sruthi, Mathews Ann Mary, Khilar Jyotish Kumar, Anto Mary et al.

This study found Aurolab aqueous drainage implants effectively lowered eye pressure for 5 years in adults with refractory glaucoma, but corneal decompensation was a significant complication.

Kassotis Alexis, Berkowitz Sean T, Patel Shriji, Schehlein Emily, Liebmann Jeffrey M, Cioffi George A et al.

This study found disposable tonometry tips and gonioscopy lenses cost nearly $1 million more over 10 years than reusable versions, highlighting a significant financial burden for eye clinics.

Asrani Sanjay G, McGlumphy Elyse J, Al-Aswad Lama A, Chaya Craig J, Lin Shan, Musch David C et al.

This review highlights that glaucoma patients have greater IOP fluctuations, often outside office hours, and these fluctuations, not just mean IOP, impact progression. Ambulatory IOP monitoring could improve care.

Steger Jennifer S, Durai Indira, Odayappan Annamalai, Raman Ramalakshmi, Sruthi Talla, Song Allisa J et al.

Timolol microdrops effectively reduced eye pressure in glaucoma patients, similar to conventional drops, with slightly less impact on heart rate, suggesting a more efficient and safer delivery.

Sleath Betsy, Beznos Bethany, Carpenter Delesha M, Budenz Donald L, Muir Kelly W, Romero Maria S et al.

This study found African American glaucoma patients and providers rarely discuss quality-of-life. Communication improved with African American providers, highlighting a need for enhanced residency training on patient QoL discussions.

Beznos Bethany, Sayner Robyn, Carpenter Delesha M, Budenz Donald L, Muir Kelly W, Annis Izabela E et al.

African American glaucoma patients often have questions, but many don't ask them all during visits, even with a prompt list. This highlights a need to improve patient-provider communication.

Palmer David J, Robin Alan L, McCabe Cathleen M, Chang David F

Multisociety experts recommend using multidose topical drugs for multiple patients until expiration and allowing patients to take home partially used meds, reducing waste and cost in ophthalmic surgery.

Wijesinghe Hiruni K, Puthuran George V, Gedde Steven J, Pradhan Chinmayee, Uduman Mohammed S, Krishnadas Subbaiah R et al.

This study found postoperative suprachoroidal hemorrhage is rare (<1%) after Aurolab glaucoma implants, but more common in children, often leading to poor visual outcomes and globe loss.

Krishna Umesh, Venkatesh Rengaraj, Srinivasan Kavitha, Odayappan Annamalai, Robin Alan L

Shalaby Wesam S, Odayappan Annamalai, Venkatesh Rengaraj, Swenor Bonnielin K, Ramulu Pradeep Y, Robin Alan L et al.

This study found visually impaired individuals, especially the blind, experienced disproportionate COVID-19 impacts, including greater healthcare access concerns and less mask-wearing. This highlights a need for targeted support and health outcome research for this vulnerable population.

Puthuran George Varghese, Palmberg Paul Frederic, Wijesinghe Hiruni Kaushalya, Shreya Thandra Sai, Krishnadas S R, Gedde Steven J et al.

This study found Aurolab glaucoma implants placed inferonasally are as safe and effective as superotemporal placement for refractory glaucoma, offering surgeons more flexibility.

Quist Tyler S, Johnson Chris A, Robin Alan L, Fingert John H

This study found TBK1-associated glaucoma presents early with severe disease and slow-to-moderate progression, suggesting very low IOP targets may benefit these patients.

Puthuran George Varghese, Palmberg Paul Frederic, Wijesinghe Hiruni Kaushalya, Pallamparthy Srilekha, Krishnadas S R, Robin Alan L

This study found Aurolab aqueous drainage implants effectively treat refractory pediatric glaucoma for up to two years, but failure rates increase significantly thereafter, highlighting a need for longer-term evaluation.

Asrani Sanjay, Robin Alan L, Serle Janet B, Lewis Richard A, Usner Dale W, Kopczynski Casey C et al.

This study found netarsudil/latanoprost FDC significantly lowered IOP more than either component alone, offering superior glaucoma treatment despite increased hyperemia.

Gordon Mae O, Higginbotham Eve J, Heuer Dale K, Parrish Richard K, Robin Alan L, Morris Patricia A et al.

The OHTS-1 Endpoint Committee improved glaucoma incidence estimates and treatment effect calculations by 23%, highlighting its value in trials with co-morbidities.

Zhao Peter Y, Rahmathullah Raheem, Stagg Brian C, Almobarak Faisal, Edward Deepak P, Robin Alan L et al.

This study found glaucoma treatments are often unaffordable globally, especially in developing nations, with timolol being the most accessible. Improving affordability is crucial to reduce global glaucoma blindness.

DeLuca Adam P, Alward Wallace L M, Liebmann Jeffrey, Ritch Robert, Kawase Kazuhide, Kwon Young H et al.

Researchers studied TBK1 gene duplications/triplications in glaucoma patients, finding varied CNV borders often within repetitive DNA, suggesting mismatched recombination as the cause. This clarifies the genetic basis of some glaucoma cases.

Johnson Chris A, Thapa Suman, George Kong Yu Xiang, Robin Alan L

An iPad app (VFE) effectively screened for moderate and advanced glaucoma visual field loss, but struggled with early loss due to high false positives. It's a fast, portable tool for specific screening needs.

Miller Sarah E, Thapa Suman, Robin Alan L, Niziol Leslie M, Ramulu Pradeep Y, Woodward Maria A et al.

A portable nonmydriatic camera measured cup-to-disc ratios similarly to standard cameras, enabling effective remote glaucoma screening, especially valuable in resource-limited settings like Nepal.

Schehlein Emily M, Im Lily T, Robin Alan L, Onukwugha Eberechukwu, Saeedi Osamah J

This study found nonmedical out-of-pocket costs for glaucoma care are significant, especially for patients with companions, living outside urban areas, or employed, impacting treatment adherence and health equity.

Schehlein Emily M, Novack Gary D, Robin Alan L

This review highlights that few new glaucoma drug classes emerged since 1996, but many novel medications and delivery systems are now in development, offering future treatment advancements.

Barnebey Howard S, Robin Alan L

This study found fixed-combination travoprost/timolol significantly improved patient adherence over 12 months compared to separate drops for glaucoma/ocular hypertension, suggesting fixed combinations can boost long-term treatment success.

Sengupta Sabyasachi, Venkatesh Rengaraj, Krishnamurthy Palaniswamy, Nath Manas, Mashruwala Abha, Ramulu Pradeep Y et al.

Both phacoemulsification and MSICS equally reduced IOP and altered angle configuration. Higher baseline IOP predicted greater reduction, suggesting both surgeries effectively lower pressure regardless of technique.

Do Anna T, Pillai Manju R, Balakrishnan Vijayakumar, Chang Robert T, Robin Alan L, Singh Kuldev et al.

Glaucoma counseling improved patient knowledge transiently, but follow-up rates remained poor across all methods. Repeated counseling may be crucial for knowledge retention and better long-term adherence.